NR3C2 and diabetic kidney disease: Hypoglycemic drugs such as metformin, SGLT2i, DPP-4i, GLP-1RA, anti-inflammation therapies, anti-senescence therapies, mineralocorticoid receptor antagonists, and stem cell therapies have also shown beneficial effects against tubular injury, potentially slowing the progression of the DKD, and thereby protecting the kidney.